Moreover, compared to infection with human rhinovirus, EV-D68 infection resulted in greater IL-17A-dependent airway inflammation and hyperresponsiveness that was responsive to anti-IL-17 antibody treatment (34), suggesting anti-IL-17 antibody as a potential therapy for severe EV-D68 respiratory disease in asthmatic patients. This evidence concerns the gene IL17A and infection.